JP2022521486A5 - - Google Patents
Info
- Publication number
- JP2022521486A5 JP2022521486A5 JP2021547309A JP2021547309A JP2022521486A5 JP 2022521486 A5 JP2022521486 A5 JP 2022521486A5 JP 2021547309 A JP2021547309 A JP 2021547309A JP 2021547309 A JP2021547309 A JP 2021547309A JP 2022521486 A5 JP2022521486 A5 JP 2022521486A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803142P | 2019-02-08 | 2019-02-08 | |
| US62/803,142 | 2019-02-08 | ||
| PCT/US2020/017283 WO2020163755A1 (en) | 2019-02-08 | 2020-02-07 | Transposon-based modifications of immune cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521486A JP2022521486A (ja) | 2022-04-08 |
| JPWO2020163755A5 JPWO2020163755A5 (https=) | 2023-02-14 |
| JP2022521486A5 true JP2022521486A5 (https=) | 2023-02-14 |
Family
ID=71947504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547309A Pending JP2022521486A (ja) | 2019-02-08 | 2020-02-07 | トランスポゾンに基づく免疫細胞の改変 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220170044A1 (https=) |
| EP (1) | EP3920941A4 (https=) |
| JP (1) | JP2022521486A (https=) |
| KR (1) | KR20220030205A (https=) |
| CN (1) | CN114502731A (https=) |
| AU (1) | AU2020218546A1 (https=) |
| CA (1) | CA3129263A1 (https=) |
| IL (1) | IL285422A (https=) |
| SG (1) | SG11202108665PA (https=) |
| WO (1) | WO2020163755A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US20220370495A1 (en) * | 2019-08-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Immune cells for adoptive cell therapies |
| KR20220062305A (ko) * | 2019-09-16 | 2022-05-16 | 맥마스터 유니버시티 | 키메라 공자극 수용체 및 이의 방법 및 용도 |
| CN115698268A (zh) | 2020-05-04 | 2023-02-03 | 萨利欧基因治疗公司 | 基于转座的疗法 |
| EP4221725A4 (en) * | 2020-10-02 | 2025-01-15 | The Regents Of The University Of California | DNA CONSTRUCTS FOR IMPROVED T-CELL IMMUNOTHERAPY OF CANCER |
| US20230392166A1 (en) * | 2020-10-21 | 2023-12-07 | Wisconsin Alumni Research Foundation | Anti-apoptotic vector and method of using the same |
| CN115894706A (zh) * | 2021-09-30 | 2023-04-04 | 北京康辰药业股份有限公司 | 靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用 |
| WO2023081815A1 (en) * | 2021-11-04 | 2023-05-11 | Saliogen Therapeutics, Inc. | Manufacturing of stem cells |
| AU2022381757A1 (en) * | 2021-11-04 | 2024-05-09 | Saliogen Therapeutics, Inc. | Immune cells with chimeric antigen receptors or chimeric autoantibody receptors |
| JP2024541501A (ja) * | 2021-11-25 | 2024-11-08 | ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ | Ｃｄ９５ポリペプチド |
| WO2023150801A2 (en) * | 2022-02-07 | 2023-08-10 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding |
| EP4479067A2 (en) * | 2022-02-14 | 2024-12-25 | The Regents Of The University Of California | Dna constructs for improved t cell immunotherapy |
| JP2025509769A (ja) * | 2022-03-15 | 2025-04-11 | ニューヨーク・ゲノム・センター，インコーポレーテッド | 改善した免疫療法のための融合タンパク質を含む方法及び組成物 |
| WO2023178358A2 (en) * | 2022-03-18 | 2023-09-21 | Dna Twopointo, Inc. | Modification of t cells |
| WO2024233669A2 (en) * | 2023-05-11 | 2024-11-14 | Saliogen Therapeutics, Inc. | Compositions and methods for treatment of cystic fibrosis |
| WO2025235576A1 (en) * | 2024-05-08 | 2025-11-13 | Saliogen Therapeutics, Inc. | Myotis lucifugus transposase engineering |
| CN121065098B (zh) * | 2025-11-10 | 2026-04-17 | 浙江大学 | 一种stat3突变的细胞产品及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5673496A (en) * | 1995-05-04 | 1996-11-21 | Arch Development Corporation | Methods for modulating t cell survival by modulating bcl-xl protein level |
| US6143291A (en) * | 1995-05-04 | 2000-11-07 | Us Navy | Methods for modulating T cell survival by modulating bcl-XL protein level |
| FR2736931B1 (fr) * | 1995-07-17 | 1997-09-19 | Univ Paris Curie | Sequences regulatrices issues du gene cd4 et a expression specifique dans les lymphocytes t matures |
| AU2003231048A1 (en) * | 2002-04-22 | 2003-11-03 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| WO2010085699A2 (en) * | 2009-01-23 | 2010-07-29 | The Johns Hopkins University | Mammalian piggybac transposon and methods of use |
| US8592211B2 (en) * | 2009-03-20 | 2013-11-26 | The Rockefeller University | Enhanced PiggyBac transposon and methods for transposon mutagenesis |
| AU2013327136A1 (en) * | 2012-10-02 | 2015-04-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| US10927384B2 (en) * | 2014-04-09 | 2021-02-23 | Dna Twopointo Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
| AU2015343013B2 (en) * | 2014-11-05 | 2020-07-16 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| CA3001312A1 (en) * | 2015-10-08 | 2017-04-13 | Dna2.0, Inc. | Dna vectors, transposons and transposases for eukaryotic genome modification |
| EP4289944A3 (en) * | 2015-10-08 | 2024-03-13 | National University Corporation Tokai National Higher Education and Research System | Method for preparing genetically-modified t cells which express chimeric antigen receptor |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| CA3015642A1 (en) * | 2016-02-26 | 2017-08-31 | Poseida Therapeutics, Inc. | Transposon system and methods of use |
| EP4043485A1 (en) * | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EP3580212A4 (en) * | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | REGULATION OF CHEMERIC ANTIGEN RECEPTORS |
| AU2018236461B2 (en) * | 2017-03-17 | 2025-03-27 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
-
2020
- 2020-02-07 JP JP2021547309A patent/JP2022521486A/ja active Pending
- 2020-02-07 AU AU2020218546A patent/AU2020218546A1/en not_active Abandoned
- 2020-02-07 US US17/429,342 patent/US20220170044A1/en not_active Abandoned
- 2020-02-07 CA CA3129263A patent/CA3129263A1/en active Pending
- 2020-02-07 EP EP20752984.3A patent/EP3920941A4/en not_active Withdrawn
- 2020-02-07 WO PCT/US2020/017283 patent/WO2020163755A1/en not_active Ceased
- 2020-02-07 CN CN202080027488.0A patent/CN114502731A/zh active Pending
- 2020-02-07 KR KR1020217028177A patent/KR20220030205A/ko not_active Abandoned
- 2020-02-07 SG SG11202108665PA patent/SG11202108665PA/en unknown
-
2021
- 2021-08-05 IL IL285422A patent/IL285422A/en unknown